Clinical trials: Pharynx Carcinoma
Nasopharyngeal Carcinoma
Predictor Analysis of Acute Radiation Oral Mucositis in NPC Patients Treated With IMRT/TOMO Combined Chemotherapy
Radiation induced oral mucositis which may result in reduced quality of life is commonly seen during radiotherapy, especially combined with chemotherapy. This study is a prospective, single center, and exploratory study.
- Trial name
- NCT03647527
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Cancinoma (NPC)
Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial
This study is aimed to evaluate the efficacy and safety of tislelizumab combined with chemotherapy and response-adapted radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma
- Trial name
- NCT07248696
- Testing
- response-adapted radiotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Chongqing University Cancer Hospital
Nasopharyngeal Carcinoma
Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma
This trial is a prospective, parallel controlled, randomized, open, multi-center phase III clinical trial. The trial will enroll 364 patients with nasopharyngeal carcinoma who are staged T1-2N0-1M0 (except T1N0M0) (UICC 8th…
- Trial name
- NCT04766359
- Testing
- Albumin-Bound Paclitaxel
- Volunteers
- 364 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nasopharyngeal Carcinoma
PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
This is a phase 3, multi-center, randomized controlled trial, with the purpose to evaluate the therapeutic efficacy and safety of PD-1 blockade (toripalimab) combined with the de-intensified chemoradiotherapy sparing concurrent…
- Trial name
- DIAMOND (NCT04907370)
- Testing
- PD-1 blocking antibody, Gemcitabine, Cisplatin (80mg/m2)
- Where
- 12 sites in China
- Volunteers
- 532 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
To Study the Feasibility and Quality of Life of Medial Group Retropharyngeal Node Sparing in Nasopharyngeal Carcinoma
This is an randomized, controlled, phase 3 clinical trial. The purpose of this study is to evaluate whether medial group retropharyngeal node （MRLN） sparing could reduce the incidence of radiation-caused dysphagia and improve…
- Trial name
- NCT03346109
- Testing
- medial group retropharyngeal node（MRLN） sparing
- Where
- China
- Volunteers
- 568 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Oropharyngeal Cancer, Dysphagia, Oropharyngeal
Liposomal Bupivacaine and Transoral Robotic Surgery
This study is for patients with oropharyngeal squamous cell carcinoma. We want to learn more about how we can optimize pain control in patients who undergo transoral robotic surgery (TORS) for oropharyngeal squamous cell…
- Conditions
- Oropharyngeal Cancer, Dysphagia, Oropharyngeal, Post Operative Pain, Transoral Robotic Surgery
- Trial name
- NCT05862792
- Testing
- Liposomal bupivacaine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Geisinger Clinic
Nasopharyngeal Carcinoma
Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare induction chemotherapy (docetaxel+cisplatin+fluorouracil) plus concurrent chemoradiotherapy with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal…
- Trial name
- NCT01245959
- Testing
- Docetaxel, cisplatin and fluorouracil, Concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 476 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma
The investigators aim to evaluate the survival benefit from triple combination of induction, concurrent and aduvant chemotherapy versus concurrent chemotherapy alone for high risk locoregionally advanced nasopharyngeal carcinoma…
- Trial name
- NCT02621970
- Testing
- Cisplatin 1, Cisplatin 2, Docetaxel
- Where
- China
- Volunteers
- 534 people
- Sponsor
- Sun Yat-sen University
Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
This phase II trial gathers information on the feasibility, safety, and effect of giving methotrexate, erlotinib, and celecoxib in treating head and neck cancer that has come back after a period of improvement (recurrent) or that…
- Conditions
- Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma, Stage IVC Lip and Oral Cavity Cancer AJCC v8, Head and Neck Cancer
- Trial name
- NCT06997068
- Testing
- Celecoxib, Erlotinib Hydrochloride, Imaging Procedure
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Nasopharyngeal Carcinoma
Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma
The investigators propose a phase II randomized-controlled study on using durvalumab in combination with induction chemotherapy followed by concurrent chemoradiation and adjuvant durvalumab, compared to induction chemotherapy…
- Trial name
- NCT04447612
- Testing
- Durvalumab, Cisplatin, Gemcitabine
- Where
- Hong Kong
- Volunteers
- 118 people
- Sponsor
- The University of Hong Kong
Nasopharyngeal Carcinoma
Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)
The investigators will add weekly cetuximab (c225) to the standard care of chemoradiation against locoregionally advanced Nasopharyngeal Carcinoma (NPC), and evaluate the toxicity and efficacy of this new regimen.
- Trial name
- NCT01712919
- Testing
- Intensity-modulated radiotherapy, Concurrent chemotherapy with paclitaxel and nedaplatin, Cetuximab
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Nasopharyngeal Carcinoma (NPC)
Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
The aim of this study is to evaluate the efficacy, adverse reactions, nutritional status analysis, and quality of life analysis of Toripalimab Plus Induction Chemotherapy Followed by Radiation Therapy Combined with Omega-3 in the…
- Trial name
- NCT07136519
- Testing
- Toripalimab, Omega-3, radiotherapy
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Guangdong Medical University
Oral Cancer, Chatbot
Enhancing Oral Cancer Awareness
To evaluate the impact of AI-powered chatbot interactions versus traditional educational handouts on increasing participants' knowledge of oral cancer and its prevention
- Conditions
- Oral Cancer, Chatbot, Patient Education, Prevention
- Trial name
- NCT06682494
- Testing
- Traditional Education, AI-powered Chatbox
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Nasopharyngeal Carcinoma (NPC), Minimal Residual Disease
Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients
This clinical trial aims to determine whether Natural Killer (NK) cell therapy administered in combination with concurrent chemoradiotherapy (CRT) can reduce recurrence in patients with advanced nasopharyngeal cancer (NPC), and…
- Conditions
- Nasopharyngeal Carcinoma (NPC), Minimal Residual Disease, Recurrent Nasopharyngeal Carcinoma, Maximum Tolerated Dose
- Trial name
- AlloNK1 (NCT07247201)
- Testing
- Allogenic expanded Natural Killer Cells (AlloNK1)
- Where
- Singapore
- Volunteers
- 31 people
- Sponsor
- Singapore General Hospital
TPF, Immunotherapy
A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma
NPC is one of the most common malignant tumors in the head and neck region of China. Currently, the main treatment regimen for LA-NPC is radical concurrent chemoradiotherapy combined with induction or adjuvant chemotherapy.
- Conditions
- TPF, Immunotherapy, Nasopharyngeal Carcinoma, Phase II Clinical Study
- Trial name
- NCT06781112
- Testing
- albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and tislelizumab ( 200mg).
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Weiwei Zhang
Nasopharyngeal Carcinoma
Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC
The purpose of this study is to explore the efficacy and safety of a combination of GP chemotherapy and tislelizumab in neoadjuvant therapy of locoregionally advanced nasopharyngeal carcinoma patients.
- Trial name
- NCT04833257
- Testing
- GP combine with Tislelizumab neoadjuvant therapy+CCRT
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma
This is a multicenter, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT combined with programmed death 1 (PD-1) antibody and chemotherapy in nasopharyngeal…
- Trial name
- NCT05524168
- Testing
- SBRT, Camrelizumab, Gemcitabine
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Sun Yat-sen University
Oropharyngeal Cancer
Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
Cancer of the oropharynx (middle, side and back walls of the throat; back of the tongue; soft palate, and tonsils), or oropharyngeal squamous cell carcinoma (OPSCC), has been on the rise in the United States.
- Trial name
- NCT02147418
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- New Mexico Cancer Research Alliance
Head and Neck Cancer
Study of Blood and Tissue Samples From Patients With Larynx Cancer, Pharynx Cancer, or Oral Cavity Cancer
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- CARIO (NCT00963326)
- Testing
- laboratory biomarker analysis
- Where
- 9 sites in France
- Volunteers
- 30 people
- Sponsor
- Centre Oscar Lambret
Nasopharyngeal Carcinoma, Single Nucleotide Polymorphisms
Polymorphisms in Key Genes of Glycolytic Pathway: Influence on Radiosensitivity in Nasopharyngeal Carcinoma
Warburg effect is an important feature of tumors,and genetic variation is one of the main factors of individual differences to radiotherapy treatment response for nasopharyngeal carcinoma(NPC).
- Conditions
- Nasopharyngeal Carcinoma, Single Nucleotide Polymorphisms, Radiosensitivity
- Trial name
- NCT02481089
- Testing
- validation group
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Hunan Province Tumor Hospital